Pfizer Operating Margin 2010-2023 | PFE

Current and historical operating margin for Pfizer (PFE) over the last 10 years. The current operating profit margin for Pfizer as of December 31, 2023 is 17.99%.
Pfizer Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2023-12-31 $58.50B $0.22B 0.38%
2023-09-30 $68.54B $9.21B 13.44%
2023-06-30 $77.94B $21.59B 27.69%
2023-03-31 $92.95B $31.88B 34.30%
2022-12-31 $100.33B $34.94B 34.83%
2022-09-30 $99.88B $33.55B 33.59%
2022-06-30 $101.28B $30.76B 30.37%
2022-03-31 $92.43B $24.15B 26.12%
2021-12-31 $81.29B $19.43B 23.91%
2021-09-30 $68.88B $17.15B 24.89%
2021-06-30 $55.12B $13.45B 24.39%
2021-03-31 $46.08B $9.91B 21.51%
2020-12-31 $41.65B $8.25B 19.81%
2020-09-30 $32.07B $2.62B 8.17%
2020-06-30 $34.47B $3.13B 9.08%
2020-03-31 $37.87B $5.32B 14.06%
2019-12-31 $40.91B $6.71B 16.40%
2019-09-30 $40.22B $5.62B 13.98%
2019-06-30 $40.84B $6.43B 15.74%
2019-03-31 $41.04B $6.14B 14.95%
2018-12-31 $40.83B $5.67B 13.89%
2018-09-30 $53.37B $14.00B 26.22%
2018-06-30 $53.24B $13.90B 26.10%
2018-03-31 $52.67B $13.66B 25.94%
2017-12-31 $52.55B $13.72B 26.11%
2017-09-30 $52.47B $13.17B 25.10%
2017-06-30 $52.35B $12.53B 23.93%
2017-03-31 $52.60B $12.26B 23.32%
2016-12-31 $52.82B $12.15B 22.99%
2016-09-30 $53.24B $12.22B 22.96%
2016-06-30 $52.29B $12.56B 24.02%
2016-03-31 $50.99B $12.68B 24.86%
2015-12-31 $48.85B $11.82B 24.20%
2015-09-30 $47.92B $12.14B 25.33%
2015-06-30 $48.20B $12.46B 25.85%
2015-03-31 $49.12B $12.82B 26.09%
2014-12-31 $49.61B $13.25B 26.71%
2014-09-30 $50.05B $14.15B 28.26%
2014-06-30 $50.33B $14.45B 28.71%
2014-03-31 $50.53B $14.78B 29.26%
2013-12-31 $51.58B $15.18B 29.44%
2013-09-30 $50.88B $14.70B 28.90%
2013-06-30 $51.19B $14.46B 28.25%
2013-03-31 $52.18B $15.04B 28.82%
2012-12-31 $54.66B $15.26B 27.93%
2012-09-30 $53.25B $14.62B 27.45%
2012-06-30 $56.90B $14.96B 26.29%
2012-03-31 $59.42B $14.12B 23.76%
2011-12-31 $61.04B $13.97B 22.88%
2011-09-30 $65.06B $13.94B 21.43%
2011-06-30 $64.44B $13.62B 21.13%
2011-03-31 $65.09B $13.80B 21.19%
2010-12-31 $65.17B $13.41B 20.58%
2010-09-30 $65.50B $11.49B 17.54%
2010-06-30 $61.13B $11.85B 19.39%
2010-03-31 $54.98B $10.77B 19.60%
2009-12-31 $49.27B $10.96B 22.24%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $156.755B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.190B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $389.835B 15.52
Merck (MRK) United States $328.029B 86.30
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
AstraZeneca (AZN) United Kingdom $204.098B 18.08
Sanofi (SNY) $123.368B 11.11
Innoviva (INVA) United States $0.992B 8.95